Last edition
News about "Richard Saynor, CEO, Sandoz"
Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics
Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.
Richard Saynor, CEO, Sandoz | 07/08/2025 | By Dineshwori | 276
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members